Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting a 200-page biotech filing packed with T-cell data is no small task. Iovance Biotherapeutics’ SEC documents weave together clinical trial efficacy, manufacturing scale-up plans and cash-burn projections—details investors need yet rarely have time to unravel.
Stock Titan’s platform turns that challenge into a two-minute read. Our AI delivers line-by-line explanations of each Iovance quarterly earnings report 10-Q filing, highlights pivotal trial endpoints in the Iovance annual report 10-K simplified, and streams Iovance Form 4 insider transactions real-time so you see executive stock moves as they post. Looking for a quick brief on a surprise data update? The Iovance 8-K material events explained module flags the section that moved the market.
Here’s what you’ll uncover on this page:
- Instant summaries that make Iovance SEC filings explained simply.
- Auto-generated dashboards comparing TIL manufacturing costs across consecutive 10-Qs.
- Alerts on Iovance insider trading Form 4 transactions before they hit the news.
- Contextual notes linking pipeline milestones to share-based compensation in the Iovance proxy statement executive compensation.
Whether you’re modeling cash runway, gauging FDA timing, or watching Iovance executive stock transactions Form 4, our AI surfaces what matters and lets you drill into original PDFs whenever you choose. Stop scrolling through dense immunotherapy jargon—start understanding Iovance SEC documents with AI and make faster, better-informed decisions.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported a routine insider equity transaction involving its Chief Regulatory Officer. On 12/01/2025, restricted stock units (RSUs) covering 5,469 shares of common stock vested, and these shares were acquired at an exercise price of $0 as part of the equity award terms.
To cover mandatory tax withholding triggered by the RSU vesting, the company withheld 2,467 shares at a price of $2.23 per share, which was not an open market sale. After this withholding, the officer beneficially owned 215,859 shares of common stock directly. The filing also notes that 27,348 RSUs from the March 1, 2024 grant remain outstanding, scheduled to vest in equal quarterly installments, each RSU representing one share of common stock.
Iovance Biotherapeutics (IOVA) filed a Form S-8 to register an additional 1,000,000 shares of common stock for its 2020 Employee Stock Purchase Plan, which was amended on June 10, 2025. The shares are the same class as those previously registered for this plan.
The filing incorporates by reference earlier S-8 registrations related to the ESPP and includes customary exhibits, including the legal opinion and auditor consent.
Iovance Biotherapeutics filed its Q3 2025 10‑Q, reporting total revenue of $67.455 million and a net loss of $91.253 million. Year to date, revenue reached $176.731 million as Amtagvi and Proleukin sales scaled.
Operating costs remained heavy: cost of sales $38.477 million, R&D $75.174 million, SG&A $34.555 million, plus $5.143 million in restructuring charges, driving a loss from operations of $94.901 million. Cash used in operations for the first nine months was $249.843 million.
Liquidity was supported by $306.8 million in cash, cash equivalents, short‑term investments, and restricted cash as of September 30, 2025, and the company states it has sufficient capital to fund planned operations for at least the next twelve months. Shares outstanding were 396,967,970 as of October 15, 2025.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics (IOVA), reported transactions dated 09/02/2025 on a Form 4. The filing shows 52,086 shares of common stock acquired upon RSU vesting at no cash price and 22,127 shares withheld by the issuer to satisfy mandatory tax withholding at a reported withholding price of $2.19 per share. After these transactions the filing reports 456,690 shares beneficially owned following the vesting event and 434,563 shares remaining after the tax-withholding deduction. The filing also details newly vested restricted stock units (RSUs): 10,417 and 41,669, with resulting beneficial ownership figures shown in the form.
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reported transactions on 09/02/2025 related to restricted stock units (RSUs). On that date 5,470 RSUs vested and were converted into shares, and the issuer withheld 2,467 shares to satisfy mandatory tax withholding. After these transactions the reporting person beneficially owned 212,857 shares (the filing shows 215,324 before withholding). The filing also discloses that 32,817 RSUs remain outstanding from the March 1, 2024 grant and remaining RSUs will vest in equal quarterly installments.
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported changes in beneficial ownership on 09/02/2025. On that date 12,697 shares of common stock were acquired upon vesting of restricted stock units (RSUs). To satisfy mandatory tax withholding, the issuer withheld 6,448 shares at an indicated per-share tax withholding price of $2.19, leaving 105,409 shares reported as beneficially owned after the withholding.
Table II shows RSU activity: 3,907 and 8,790 RSUs were reported as vested under two grants, representing underlying common stock amounts reflected in the filing. The reporting person signed the Form 4 on 09/04/2025.
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), reported equity changes on 09/02/2025. Restricted stock units (RSUs) vested that day, resulting in the acquisition of 12,306 common shares (recorded as Code M) at no cash price. To satisfy mandatory tax withholding on the vesting, the issuer withheld 6,250 shares (recorded as Code F) at a price of $2.19 per share rather than an open-market sale, leaving 99,689 shares beneficially owned after the transactions. The filing also lists vested RSU components of 3,516 and 8,790 underlying common shares, with remaining RSU schedules described in the explanatory notes.
Iovance Biotherapeutics, Inc. (IOVA) submitted an 8-K reporting other events and provided a corporate presentation as an exhibit. The filing lists written and soliciting communications under Rule 425 and Rule 14a-12, plus pre-commencement communications under Rules 14d-2(b) and 13e-4(c). The disclosure includes Exhibit 99.1, a corporate presentation dated
Iovance Biotherapeutics, Inc. filed an 8-K reporting written and soliciting communications under several securities rules and that it has engaged Jefferies to use commercially reasonable efforts to sell the company’s common shares from time to time under customary trading parameters. The filing references pre-commencement and solicitation rules and states the communication is dated
FAQ
What is the current stock price of Iovance Biotherp (IOVA)?
What is the market cap of Iovance Biotherp (IOVA)?
